Mira Kyivska

What's behind United Therapeutics's latest 3.6% stock surge?

What's behind United Therapeutics's latest 3.6% stock surge?
United Therapeutics rises 3.65% today

United Therapeutics Corporation (UTHR) climbed 3.65% after the family trust of Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a scheduled Rule 10b5-1 plan, drawing increased investor attention. The advance is supported by the stock holding above all major moving averages, with momentum indicators backing the near-term uptrend, even as the longer-term trend alignment remains bearish and could restrain further gains.

UTHR price prediction
24H 0.09%
$591.72
48H 0.37%
$593.35
7D 0.62%
$594.85
1M 7.83%
$637.46
3M 22.1%
$721.84
6M 40.18%
$828.72
12M 40.2%
$828.82
Current price: $591.17 -2.1550 0.36%
Closed 11/13
Daily range 587.00 Arrow from to Icon 598.84
Weekly range 556.66 Arrow from to Icon 598.84
Loading...

Highlights

  • A family trust linked to Martine A. Rothblatt exercised 9,500 United Therapeutics stock options at $117.76 per share and sold 9,500 shares at prices between $542.73 and $556.48 under a pre-arranged trading plan.
  • The trust continues to hold 280,910 United Therapeutics stock options after the recent exercise and sale transactions.
  • Shares of United Therapeutics trade above short-, medium-, and long-term moving averages, with technical indicators showing constructive momentum and resistance at $558.29; the five-day range is expected at $533.73 to $566.95.

Option exercise and stock sales by CEO trust influence market flows

On October 7, 2026, a family trust linked to Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options at $117.76 per share and sold 9,500 shares at weighted-average prices between $542.73 and $556.48. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The trust retained 280,910 stock options after these actions.

Anton Kharitonov, expert at Traders Union, sees United Therapeutics’ recent option exercise and share sale as a potential red flag despite the stock’s short-term momentum. He believes the persistent bearish trend beneath current technical strength suggests limited upside potential. Sentiment around the CEO’s sale under a Rule 10b5-1 plan may also curb investor confidence. Kharitonov notes that overbought conditions and long-term misalignment expose the stock to near-term fatigue. "Traders should remain cautious and closely monitor for a break below immediate support at $533.73 for signs of exhaustion," he warns.
Viktoras Karapetjanc, expert at Traders Union, highlights United Therapeutics’ strong technical setup and sustained bullish momentum above all key moving averages. He sees institutional activity and scheduled insider sales as healthy signs that do not disrupt the overall uptrend structure. Karapetjanc expects further growth, with market dynamics favoring buyers and a robust probability of continued upside. "With price consolidating near highs and the bullish structure intact, I expect a breakout above $558.29 to unlock the next leg upward," he asserts.
Parshwa Turakhiya, analyst, views United Therapeutics as a short-term play driven by strong momentum and active market sentiment. He notes intraday volatility remains elevated and oscillators point to possible near-term exhaustion. Turakhiya suggests traders watch for fast swings between $533.73 and $566.95, with opportunity tied to the next breakout or breakdown. "The setup invites nimble strategies — I recommend capitalizing on sharp moves while sentiment stays upbeat but caution is warranted if momentum fades," he says.
United Therapeutics Corporation asset chart
United Therapeutics Corporation price dynamics. Source: TradingView.

Short-term bullish signals tempered by longer-term bearish alignment

United Therapeutics is trading above the 20-day, 50-day, and 200-day moving averages ($509.82, $512.15, and $525.95), indicating bullish momentum on all timeframes. The price is approaching near-term resistance at $558.29, with immediate support at $550.01. Despite the short-term bullish setup, the longer-term trend alignment remains bearish, which could temper sustained upside momentum. Momentum indicators are mostly constructive: MACD and ADX show buy signals, RSI at 55.71 is neutral-to-bullish, and CCI favors buyers. Stochastic RSI is starting to flag overbought conditions. Bull/Bear Power at 20.44 indicates a buyer-dominated environment and signals overbought territory, while the Awesome Oscillator remains neutral. Intraday volatility stands at 3.99%, and the tone is strong, with some oscillators signaling near-term exhaustion.

Previously it was reported that United Therapeutics gained after a court ruled in its favor in a key patent dispute against Liquidia, impacting market dynamics in pulmonary hypertension treatments. The current technical environment adds a new dimension, as the stock's ability to consolidate or break above the $558.29 resistance level is now a critical factor for near-term trading direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.